Latest post

The new Perspectives Magazine 2020 is here

The new issue of Oxurion Perspectives magazine is here. Read about last year's highlights and the ambitious times ahead.

back of the eye diseases, science community,

Progressing development of therapies for retinal vascular disorders and diabetic eye disease

Patrik De Haes, M.D., CEO of Oxurion, and Thomas Clay, Chairman of the Board, review the year 2019.

back of the eye diseases, science community,

Pravin Dugel, M.D.: “Biological signal for efficacy of THR-149”

“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.

back of the eye diseases, science community,

Phase 1 trial showed THR-149 is a highly potent plasma kallikrein inhibitor to treat DME

In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).

science community

A strategic focus for Oxurion: researching and developing non-VEGF pathways

Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.

science community

“An aspiring name to reflect our focus and ambition”

“The new name comes from combining the words Oxygen and Orion”, explains CEO Patrik De Haes, MD. “Raising oxygen levels in cells plays a key role in helping prevent and reverse ...